Ph.D., Assistant Professor, University of Pennsylvania Perelman School of Medicine
Dr. Posey is a geneticist proficient in the development and pre-clinical characterization of chimeric antigen receptors (CARs) and other engineered T cell strategies for cancer immunotherapy. He is developing novel CAR-T cell therapies that selectively targets a cell surface glycopeptides and glycoantigens found exclusively in cancers. The major objective of his research is to increase the efficacy of engineered T cells in solid tumors. Dr. Posey began his work in the CAR-T cell field in 2011. His initial work is currently being translated in a phase I clinical trial and he hopes to translate additional therapeutics in the next few years.
Session Abstract – PMWC 2020 Silicon Valley
Session Synopsis: CAR-T cell therapy has evolved from an arcane approach under study in a handful of academic centers to a commercialized immunotherapy that is now being integrated into standard cancer care. The session will highlight some of the recent scientific advances that have begun to define major mechanisms of resistance to CAR-T cell therapy in B cell malignancies and identify the challenges that need to be addressed if these agents are to find broader applications in other hematological cancers and solid tumors.